Who are Anti-Thymocyte Globulins's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CroFab, HIV immune globulin solution, Cy-ATG.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-thymocyte-globulins.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anti-Thymocyte Globulins — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-Thymocyte Globulins (Anti-Thymocyte Globulins) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal antibody; immunosuppressant. Area: Immunology; Hematology/Transplantation.

marketed Polyclonal antibody; immunosuppressant T lymphocyte surface antigens (CD2, CD3, CD4, CD8, and other T cell markers) Immunology; Hematology/Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Anti-Thymocyte Globulins (Anti-Thymocyte Globulins) — Tianjin First Central Hospital. Anti-thymocyte globulin (ATG) depletes T lymphocytes by binding to and eliminating thymus-derived T cells, suppressing the adaptive immune response.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-Thymocyte Globulins TARGET	Anti-Thymocyte Globulins	Tianjin First Central Hospital	marketed	Polyclonal antibody; immunosuppressant	T lymphocyte surface antigens (CD2, CD3, CD4, CD8, and other T cell markers)
CroFab	CroFab	Instituto Bioclon S.A. de C.V.	marketed	Antivenom (polyclonal antibody fragments)	Crotalid venom toxins (phospholipase A2, serine proteases, metalloproteinases)
HIV immune globulin solution	HIV immune globulin solution	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Immune globulin (polyclonal antibody preparation)	HIV envelope proteins (gp120/gp41)
Cy-ATG	Cy-ATG	Cooperative Study Group A for Hematology	phase 3	Immunosuppressive agent / Polyclonal antibody	T lymphocytes (CD2, CD3, CD4, CD8 antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal antibody; immunosuppressant class)

Tianjin First Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-Thymocyte Globulins — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-thymocyte-globulins. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab